Company news
Cabaletta Bio, Inc. (NASDAQ:CABA) news
Every Cabaletta Bio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cabaletta Bio to Participate in Upcoming Investor Conferences
September 1, 2026
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus ...
June 3, 2026
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
May 4, 2026
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
April 28, 2026
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
April 28, 2026
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated M...
April 27, 2026
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
April 14, 2026
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 23, 2026
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
Cabaletta Bio Announces 2026 Strategic Priorities
January 12, 2026
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
January 12, 2026
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
November 4, 2025
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
October 27, 2025
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
October 14, 2025
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 20...
October 9, 2025
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 27, 2025
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Cabaletta Bio Announces Pricing of Public Offering of Securities
June 11, 2025
Cabaletta Bio Announces Proposed Public Offering of Securities
June 11, 2025
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EUL...
June 11, 2025
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 29, 2025
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
May 15, 2025
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 31, 2025
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
March 19, 2025
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
February 26, 2025
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-c...
February 18, 2025
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at Feb...
February 18, 2025
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
February 11, 2025
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
January 29, 2025
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
January 13, 2025
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
November 26, 2024
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 6, 2024
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 25, 2024
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 8, 2024
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 2, 2024
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
June 14, 2024
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 1, 2024
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
January 8, 2024